Artal Group S.A. trimmed its stake in shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) by 20.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 200,000 shares of the company’s stock after selling 50,000 shares during the quarter. Artal Group S.A. owned about 0.62% of Jounce Therapeutics worth $3,116,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently made changes to their positions in JNCE. Bank of New York Mellon Corp acquired a new stake in shares of Jounce Therapeutics during the 1st quarter worth approximately $385,000. TIAA CREF Investment Management LLC acquired a new stake in shares of Jounce Therapeutics during the 1st quarter worth approximately $229,000. Geode Capital Management LLC acquired a new stake in shares of Jounce Therapeutics during the 1st quarter worth approximately $1,573,000. Paloma Partners Management Co acquired a new stake in shares of Jounce Therapeutics during the 1st quarter worth approximately $212,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Jounce Therapeutics during the 1st quarter worth approximately $271,000. Institutional investors and hedge funds own 40.95% of the company’s stock.
Several research firms recently commented on JNCE. J P Morgan Chase & Co set a $28.00 target price on Jounce Therapeutics and gave the company a “buy” rating in a research report on Monday, November 13th. Robert W. Baird restated an “outperform” rating and issued a $30.00 target price on shares of Jounce Therapeutics in a research report on Monday, September 18th. Finally, Zacks Investment Research upgraded Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, August 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $23.67.
Jounce Therapeutics, Inc. (NASDAQ JNCE) traded up $0.31 on Monday, reaching $14.59. The company had a trading volume of 214,200 shares, compared to its average volume of 159,224. Jounce Therapeutics, Inc. has a 12-month low of $11.05 and a 12-month high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Monday, November 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.12. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The firm had revenue of $18.10 million for the quarter, compared to analysts’ expectations of $20.00 million. Jounce Therapeutics’s quarterly revenue was up 7.1% on a year-over-year basis. equities analysts anticipate that Jounce Therapeutics, Inc. will post -0.77 earnings per share for the current year.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.